TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Grant

Awarded By

Total Award Amount

  • 87926.00

    • Direct Costs

  • 69783.00

    • Sponsor Award Id

    • Contributor

  • Erica Stringer-Reasor M.D.   Investigator  
  • Gabrielle Rocque M.D.   Investigator  
  • Lisle Nabell M.D.   Investigator